Intralink-Spine (ILS) is a company formed to develop, manufacture, market, and sell a tissue modifying reagent that can be injected into the intervertebral disc of the human spine to increase crosslinking in the native collagen matrix.
ILS, a privately held medical device company focused on the treatment of degenerative disc disease and low back pain, announced today that it has been awarded a $750,000 Small Business Innovation Research (SBIR) Grant from the National Institutes of Health (NIH) for pre-clinical studies of its NEXT technology.
The NEXT device is designed to immediately strengt...
